Comparing COVID-19 vaccine effectiveness in Türkiye: heterologous, inactivated, and mRNA vaccines
Journal of Infection in Developing Countries, cilt.20, sa.5, ss.637-648, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 20 Sayı: 5
- Basım Tarihi: 2026
- Doi Numarası: 10.3855/jidc.21743
- Dergi Adı: Journal of Infection in Developing Countries
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Directory of Open Access Journals, Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest)
- Sayfa Sayıları: ss.637-648
- Anahtar Kelimeler: protective effectiveness, public health, severe disease outcomes, vaccine strategy, COVID-19, pandemic
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Introduction: This study investigates the effectiveness of different coronavirus disease (COVID-19) vaccines in preventing hospitalization, ICU admissions, and mortality in Türkiye, upon comparing the responses to heterologous, inactivated, and mRNA vaccines. Methodology: Data were gathered from 24,538 individuals, aged ≥ 18 years, whose COVID-19 status was confirmed through PCR testing. An analysis of the survival distributions for six vaccine types showed significant differences in severe disease outcomes, with distinct patterns observed for individuals older and younger than 65 years. Results: Vaccines, including two-dose mRNA, both heterologous and homologous, showed the most protective and durable vaccine effectiveness. Homologous and heterologous inactivated vaccines demonstrated statistically significant reductions in severe COVID-19 outcomes for individuals aged > 65 years compared to unvaccinated individuals. Conclusions: The results suggest that an early deployment of inactivated vaccines, despite being less advanced, may have played an important role in providing timely protection, mitigating severe outcomes, especially in countries with limited access to novel vaccine technologies. This study provides key insights for shaping future vaccine strategies and public health policies, particularly in regions with varying access to healthcare resources.